Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) used to treat various types of macular-degenerative diseases such as neovascular (wet) age-related macular degeneration, diabetic retinopathy, macular edemas and myopic choroidal neovascularization. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.
Subject to FDA's approval of this BLA, the product will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Said submission represents the most recent milestone for Bioeq's ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA and UK MHRA already in July this year.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented:
“The submission of a BLA to the FDA is a major milestone for any therapeutic and brings hope to patients across the US. This announcement carries a tangible promise of treatment choice and improved access to those who suffer from debilitating vision loss, including age-related macular degeneration. This is another representation of our commitment to providing safe and effective medicines to patients.”
1) Lucentis ® is a registered trademark of Genentech Inc.
About Ranibizumab biosimilar
The Ranibizumab biosimilar, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis®.
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005187/en/
Contact information
Joseph Reeds
Head of Marketing, Polpharma Biologics
Joseph.reeds@polpharmabiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Expands Global Market Access with the Taipei Exchange18.11.2025 17:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced access to the Taipei Exchange (TPEx), further expanding its global reach. Eligible clients of Interactive Brokers can now trade equities, ETFs, and Taiwan Depositary Receipts (TDRs) listed on TPEx, alongside products from over 160 global exchanges from a single platform. This extends the opportunity set available to global investors seeking Asian exposure, including the growth potential afforded by emerging small and medium-sized companies listed on the TPEx. Interactive Brokers is one of the few global trading platforms connected to TPEx, a leading Asian exchange for shares of small and medium-sized enterprises (SMEs). Through TPEx, clients can diversify their portfolios to include emerging, high-tech, and creative industries, as well as SMEs and micro-enterprises across Taiwan’s developing economy. To simplify trading, Interactive Brokers will facilitate TPEx trades with an automatic FX conversion be
Andersen Consulting Enters Collaboration Agreement with Business Meets Culture18.11.2025 16:30:00 EET | Press release
Andersen Consulting expands its global reach through a Collaboration Agreement with Business Meets Culture (BMC), a global strategy consultancy with locations in Latin American, Europe, and the U.S. Anchored in cultural intelligence and human insight, BMC specializes in strategy, brand strategy, commercial planning, innovation, and transformation; always. Through proprietary approaches and cross-disciplinary teams, BMC helps companies connect strategy to people by translating trends, behaviors, and business tensions into meaningful opportunities for business growth. The firm works with leading companies in various industries including consumer goods, financial services, telecommunications, technology. “Collaborating with Andersen Consulting allows us to amplify the reach and impact of our culturally grounded strategic work,” said Fernando Parodi, CEO of BMC. “Together, we’re positioned to offer organizations sharper perspective, greater foresight, and actionable strategies that drive s
Aspect Expands Cloud Workforce Experience and Developer Tools to New Regions and Introduces AI-Powered Forecasting18.11.2025 16:00:00 EET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, today announced its Q4 2025 product release, delivering AI-powered predictive forecasting for call volume, regional expansion into Canada, UK, and Europe, and new employee performance capabilities. The release represents a significant step forward in Aspect's mission to empower workforces with intelligent, modern tools that drive operational efficiency and employee engagement. AI-Driven Forecasting Brings New Precision and Agility to Workforce Planning The enhanced Forecast Dashboard introduces Predictive Forecasting with built-in AI intelligence. This new feature automatically generates four-week call volume forecasts that refresh daily, eliminating manual setup and enabling planners to make faster, more confident scheduling decisions. By analyzing historical data with advanced algorithms, it delivers more accurate, assumption-free predictions that adapt to changing demand patterns. "Forecasting is one of the mo
Gurobi Releases Version 13.0 with Improved Performance and New Solving Capabilities18.11.2025 16:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce the release of Gurobi 13.0. This latest version represents a significant advancement in Gurobi’s mission to help organizations tackle increasingly complex optimization challenges with greater speed and flexibility. Version 13.0 introduces performance improvements across core model types, new algorithm support for large-scale and nonlinear problems, GPU acceleration, and expanded cloud-native functionality. “Today’s organizations face optimization challenges that are often domain-specific and more complex than ever,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “With Gurobi 13.0, we’re extending our technology to handle even larger models and more nonlinear problem types—delivering measurable speed-ups and greater flexibility across a wide range of applications.” Enhancements in the Gurobi Optimizer 13.0 include: A faster core solver, particularly for difficult mixed-integer programmin
FireMon Expands Zero Trust Microsegmentation Coverage with Illumio, VMware NSX, and Zscaler18.11.2025 16:00:00 EET | Press release
FireMon, the leading network security and firewall policy management company, today detailed expanded support for Zero Trust microsegmentation across hybrid environments, including a deeper integration with Illumio and continued coverage for VMware NSX and Zscaler. By normalizing, analyzing, and continuously validating segmentation intent across network, virtual, and host enforcement points, FireMon helps security teams operationalize Zero Trust at enterprise scale. “The future isn’t more consoles,” said Jody Brazil, CEO of FireMon. “It’s one policy playbook that proves control efficacy every day and the evidence to back it up.” Organizations using FireMon to unify segmentation and firewall governance report measurable outcomes, including up to a 90% reduction in compliance reporting time through consolidated policy data and faster validation and change reviews across the hybrid networks. They also eliminate blind spots between virtual, host, and network enforcement points, strengtheni
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom